Kevin was most recently Senior Director and US Head of Spectroscopy within Product Development at GlaxoSmithKline (GSK) leading a team of technical experts in spectroscopy, spectrometry, degradation chemistry, preparative chromatography, impurity isolation and identification, molecular structure determination, trace level organic (genotoxin) analysis, trace metals analysis, Process Analytical Technology, analytical method development, validation and transfer, technical problem solving for marketed product and other project support, and technology evaluation and implementation.
His core expertise is in NMR spectroscopy, genotoxin analysis and to a lesser extent degradation chemistry. He has managed over two dozen staff across multiple sites and has experience building teams, developing staff and leading and participating on local and global matrix and management teams to achieve project and business objectives. He has related business experience analyzing resource needs and utilization and has had responsibility for multi-million dollar global capital asset inventories, budgets and acquisitions.
Kevin has participated on working parties (PhRMA, PQRI) and organizing committees for technical conferences and published and presented as well. He has received several recognition awards for key project contributions including a Platinum Award and a Pipeline Award while at GSK.
Kevin has a Ph.D. in Physical Organic Chemistry from the University of Nebraska, a B.S. in Chemistry from the University of Maryland and worked for the Robert W. Johnson Pharmaceutical Research Institute prior to joining Glaxo.